| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer
|
Ilié, Marius
|
|
|
166 |
C |
p. 1-8
|
artikel
|
| 2 |
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors
|
Lin, Lin
|
|
|
166 |
C |
p. 98-106
|
artikel
|
| 3 |
Applying utility values in cost-effectiveness analyses of lung cancer screening: A review of methods
|
Ngo, Preston J.
|
|
|
166 |
C |
p. 122-131
|
artikel
|
| 4 |
Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study
|
Slimano, Florian
|
|
|
166 |
C |
p. 114-121
|
artikel
|
| 5 |
A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer
|
Zhao, Joseph J
|
|
|
166 |
C |
p. 17-26
|
artikel
|
| 6 |
Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network
|
Robert, Nicholas J.
|
|
|
166 |
C |
p. 197-204
|
artikel
|
| 7 |
Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays “cold” immune characteristics in Non-small cell lung cancer
|
Zhu, Yan-juan
|
|
|
166 |
C |
p. 189-196
|
artikel
|
| 8 |
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial
|
Naidoo, Jarushka
|
|
|
166 |
C |
p. 84-93
|
artikel
|
| 9 |
Clinical practices for non-neoplastic thymic lesions: Results from a multidisciplinary cohort
|
Joubert, Virginie
|
|
|
166 |
C |
p. 76-83
|
artikel
|
| 10 |
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib
|
Bauml, Joshua M.
|
|
|
166 |
C |
p. 270-278
|
artikel
|
| 11 |
Contents
|
|
|
|
166 |
C |
p. v-vii
|
artikel
|
| 12 |
Corrigendum to “The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment” [Lung Cancer 165C (2022) 124–132]
|
McLean, Anna E.B.
|
|
|
166 |
C |
p. 252
|
artikel
|
| 13 |
Disparate genomic characteristics of patients with early-stage lung adenocarcinoma manifesting as radiological subsolid or solid lesions
|
Li, Hao
|
|
|
166 |
C |
p. 178-188
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
166 |
C |
p. iii
|
artikel
|
| 15 |
EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature
|
Copia Sperandio, Rubens
|
|
|
166 |
C |
p. 94-97
|
artikel
|
| 16 |
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial
|
Riudavets, Mariona
|
|
|
166 |
C |
p. 255-264
|
artikel
|
| 17 |
Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer
|
Tang, Monica
|
|
|
166 |
C |
p. 40-48
|
artikel
|
| 18 |
Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden
|
Tan, Chichun
|
|
|
166 |
C |
p. 265-269
|
artikel
|
| 19 |
“HRCT predictors of GGO surgical resection: Histopathological and molecular correlation in the era of lung sparing surgery”
|
Volterrani, L.
|
|
|
166 |
C |
p. 70-75
|
artikel
|
| 20 |
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
|
Huang, Le-Tian
|
|
|
166 |
C |
p. 9-16
|
artikel
|
| 21 |
Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance
|
Sun, Ke
|
|
|
166 |
C |
p. 63-69
|
artikel
|
| 22 |
Optimizing the radiomics-machine-learning model based on non-contrast enhanced CT for the simplified risk categorization of thymic epithelial tumors: A large cohort retrospective study
|
Feng, Xiu-Long
|
|
|
166 |
C |
p. 150-160
|
artikel
|
| 23 |
Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report
|
Skribek, Marcus
|
|
|
166 |
C |
p. 132-134
|
artikel
|
| 24 |
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)
|
Van der Weijst, Lotte
|
|
|
166 |
C |
p. 228-241
|
artikel
|
| 25 |
Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer
|
Killingberg, Kristin Toftaker
|
|
|
166 |
C |
p. 49-57
|
artikel
|
| 26 |
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non–small cell lung cancer
|
Santoro, Armando
|
|
|
166 |
C |
p. 170-177
|
artikel
|
| 27 |
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
|
Levy, Benjamin
|
|
|
166 |
C |
p. 107-113
|
artikel
|
| 28 |
Postoperative radiotherapy (PORT) in NSCLC: The end of a love? It is never too good to trust what appears
|
Arcangeli, Stefano
|
|
|
166 |
C |
p. 250-251
|
artikel
|
| 29 |
Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients
|
Fournel, Ludovic
|
|
|
166 |
C |
p. 221-227
|
artikel
|
| 30 |
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
|
Edelman, Martin J.
|
|
|
166 |
C |
p. 135-142
|
artikel
|
| 31 |
Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review
|
Juarez-Garcia, Ariadna
|
|
|
166 |
C |
p. 205-220
|
artikel
|
| 32 |
Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer
|
Claerhout, Sofie
|
|
|
166 |
C |
p. 242-249
|
artikel
|
| 33 |
The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese lung large cell neuroendocrine carcinoma
|
Li, Ye
|
|
|
166 |
C |
p. 161-169
|
artikel
|
| 34 |
The impact of a pathologist’s personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer
|
Butter, Rogier
|
|
|
166 |
C |
p. 143-149
|
artikel
|
| 35 |
Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes
|
Zhang, Jianrong
|
|
|
166 |
C |
p. 27-39
|
artikel
|
| 36 |
Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer
|
Schmid, Sabine
|
|
|
166 |
C |
p. 58-62
|
artikel
|
| 37 |
What is the current role of immunotherapy in EGFR mutant advanced NSCLC?
|
Velez, Maria A.
|
|
|
166 |
C |
p. 253-254
|
artikel
|
Tijdschrift beschrijving